Arvanil and olvanil also exert anti-proliferative effects in human breast cancer cells MCF-7 and T-47D by suppressing the prolactin receptor- and/or nerve growth factor (NGF)-induced cell proliferation via activation of the CB1 receptor that leads to the inhibition of adenylyl cyclase and stimulation of the MAPK pathway [33]. This evidence concerns the gene NGF and breast cancer.